Navigation Links
Statin plus cancer drug deliver combo punch to brain cancer cells

Building on newly discovered genetic threads in the rich tapestry of biochemical signals that cause cancer, a Johns Hopkins Kimmel Cancer Center team has dramatically killed brain cancer cells by blocking those signals with a statin and an experimental antitumor drug.

The unlikely pairing of cholesterol-lowering lovastatin and cyclopamine killed 63 percent of medulloblastoma cells grown in the laboratory. By contrast, using either agent alone wiped out fewer than 20 percent of cells. The Hopkins researchers published their findings in the January issue of the American Journal of Pathology.

The researchers caution that the cyclopamine-lovastatin combination has yet to be tested in animals, much less people, but they conclude that the tumor cell-killing by the combo is tantalizing. Cyclopamine works by blocking the so-called "hedgehog" pathway, long known to promote and guide cell and organ growth. Excessive growth is the chief characteristic of cancer. The investigators believe that blocking hedgehog with cyclopamine makes cancer cells more susceptible to lovastatin.

Along with its cholesterol-clogging effects, lovastatin, sold under the trade name Mevacor, is known to curb destruction of proteins that put the brakes on cell growth, causing cancer cells to self-destruct through a process called apoptosis. The effects of the statin already is being studied in people at high risk for the deadly skin cancer, melanoma.

First extracted from corn lilies in the 1950s, cyclopamine is a powerful toxin known to stunt fetal development and cause birth defects in humans and animals. Its connection to anti-cancer efforts grew out of later insights into its blockage of hedgehog, which gets its name from spiky hairs that develop on fruit flies lacking the signal.

"We already knew from earlier research that hedgehog controls brain cell survival and growth, and that blocking signals in this pathway may stop uncontrolled growth of canc er cells," says Charles Eberhart, M.D., Ph.D., associate professor of pathology, ophthalmology and oncology. "But the new work shows the hedgehog blockade may halt another powerful cell-survival signal, and lovastatin could provide the added boost necessary to kill more cancer cells."

Specifically, Eberhart found links between the expression of key hedgehog-related genes in medulloblastoma cells and another cell signal already tied to cancer, Bcl-2. Eberhart and his team believed that combination of a hedgehog blockade and a pro-apoptosis drug like lovastatin would kill more cancer cells.

"Our experiments suggest that hedgehog's action is woven together with Bcl-2, best known for its role in causing B-cell lymphomas," he says. "Cancer cells thwart suicide by overproducing Bcl-2, assuring them a long life."

When the Hopkins researchers noticed that Bcl-2 and hedgehog expression increased in tandem in medulloblastoma cells, they tried adding hedgehog-blocking cyclopamine to the cells and found that Bcl-2 production dwindled and tumor cells died off.

Lead author and pathology fellow Eli E. Bar, Ph.D., said he was "surprised by the degree to which the drug combination was so effective."

According to Eberhart, only half of children with medulloblastoma survive. "And those that do survive can suffer debilitating side effects caused by current toxic therapies."


'"/>

Source:Johns Hopkins Medical Institutions


Related biology news :

1. Statins have neutral effect on risk of cancer
2. Statins stop hepatitis C virus from replicating
3. Statin treatment improves spatial memory in mouse models of Alzheimers
4. Viral DNA sequence a possible trigger for breast cancer
5. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
6. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
7. Columbia research lifts major hurdle to gene therapy for cancer
8. Combination therapy boosts effectiveness of telomere-directed cancer cell death
9. Mitochondrial DNA mutations play significant role in prostate cancer
10. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
11. BRCA1 causes ovarian cancer through indirect, biochemical route
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... DIEGO, CALIF. (PRWEB) , ... April 26, 2017 ... ... Day? Lajollacooks4u, San Diego’s premiere team-building and cooking events company, offers one-of-a-kind ... classes. , Menus specialize in California cuisine, and guests leave inspired with ...
(Date:4/26/2017)... , ... April 25, 2017 , ... LABS, Inc. (LABS) ... were added to its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and ... was only able to offer NAT screening for blood donors under an Investigational New ...
(Date:4/26/2017)... Va. (PRWEB) , ... April 26, 2017 , ... ... make headlines and drive high-level conversations among healthcare industry stakeholders, the discussion surrounding ... Environment – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted by ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... leading supplier of Common Lisp (CL) development tools, and market leader for ... includes key performance enhancements now available within the most effective system for developing ...
Breaking Biology Technology: